Piper Jaffray & Co.

In a report published Friday, Piper Jaffray & Co. reiterated its Neutral rating on Pacific Sunwear of California (NASDAQ: PSUN), but slightly lowered its price target from $2.50 to $2.00. Piper Jaffray noted, “We are maintaining our Neutral rating on PSUN shares following the company's holiday...

In a report published Friday, Piper Jaffray & Co. reiterated its Neutral rating on Deckers Outdoor Corp. (NASDAQ: DECK), but slightly lowered its price target from $35.00 to $34.00. Piper Jaffray noted, “We are reiterating our caution on DECK shares and lowering earnings estimates and price...

In a report published Friday, Piper Jaffray & Co. downgraded its rating on Aeropostale (NYSE: ARO) from Overweight to Neutral, and lowered its price target from $15.00 to $13.00. Piper Jaffray noted, “Amid further deceleration in underlying business trends, we are heavily conflicted in our...

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on HSN (NASDAQ: HSNI), and raised its price target from $64.00 to $80.00. Piper Jaffray noted, “HSN launched a comprehensive redesign of its customer interface across all of its digital platforms yesterday,...

In a report published Wednesday, Piper Jaffray & Co. reiterated its Neutral rating on Apollo Group (NASDAQ: APOL), and slightly raised its price target from $24.00 to $25.00. Piper Jaffray noted, “Aggressive cost management efforts translated into a F1Q EPS beat for Apollo, but lingering...

In a report published Monday, Piper Jaffray & Co. reiterated its Overweight rating and $100.00 price target on athenahealth (NASDAQ: ATHN). Piper Jaffray noted, “Earlier today, ATHN announced signing a definitive agreement to acquire EPOC for $11.75 per share. The deal is expected to be...

In a report published Monday, Piper Jaffray & Co. reiterated its Neutral rating on Sequenom (NASDAQ: SQNM), and slightly raised its price target from $4.50 to $5.00. Piper Jaffray noted, “Sequenom announced positive preliminary 2012 results, with revenue increasing ~59% year-over-year,...

In a report published Friday, Piper Jaffray & Co. reiterated its Neutral rating on Synageva BioPharma Corp. (NASDAQ: GEVA), but lowered its price target from $57.00 to $53.00. Piper Jaffray noted, “We are incrementally more positive on GEVA following review of the company's S-3 filing which...

In a report published Friday, Piper Jaffray & Co. downgraded its rating on Endo Health Solutions (NASDAQ: ENDP) from Overweight to Neutral, and lowered its price target from $37.00 to $28.00. Piper Jaffray noted, “We are downgrading Endo to a Neutral from an Overweight and lowering our price...

In a report published Friday, Piper Jaffray & Co. initiated coverage on Cytokinetics (NASDAQ: CYTK) with an Overweight rating and $4.00 price target. Piper Jaffray noted, “We are initiating on Cytokinetics with an Overweight rating and $4 price target. In our view, the company's platform for...

In a report published Friday, Piper Jaffray & Co. downgraded its rating on Cepheid (NASDAQ: CPHD) from Overweight to Neutral, and lowered its price target from $42.00 to $34.00. Piper Jaffray noted, “As a reminder, Cepheid experienced two manufacturing issues in FY12, with a plastic parts...

In a report published Friday, Piper Jaffray & Co. initiated coverage on BioDelivery Sciences International (NASDAQ: BDSI) with a Neutral rating and $5.00 price target. Piper Jaffray noted, “We are initiating on BioDelivery Sciences at Neutral with a 12-month price target of $5. BioDelivery...

In a report published Friday, Piper Jaffray & Co. initiated coverage on Avanir Pharmaceuticals (NASDAQ: AVNR) with an Overweight rating and $6.00 price target. Piper Jaffray noted, “We are initiating on Avanir with an Overweight rating and $6 price target. Avanir develops drugs for...

In a report published Friday, Piper Jaffray & Co. initiated coverage on Alexza Pharmaceuticals (NASDAQ: ALXA) with a Neutral rating and $5.00 price target. Piper Jaffray noted, “We are initiating coverage on Alexza with a Neutral rating and 12-month price target of $5. Alexza reformulates...

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating and $103.00 price target on Watson Pharmaceuticals (NYSE: WPI). Piper Jaffray noted, “On Monday, Mallinckrodt (Covidien's pharma business) became the first filer to gain approval of a Concerta generic. While...